Table 1 Characteristics of the 533 GC patients enrolled into this study
From: Long term follow up and retrospective study on 533 gastric cancer cases
Variables | Total n (%) | Events n (%) | Median GC-specific OS (95% CI) (mo) | P value |
|---|---|---|---|---|
Age (yr) | ||||
  ≤ 65 | 380 (71.3) | 178 (46.8) | 51.7 (39.7-63.7) | < 0.001 |
  > 65 | 153 (28.7) | 100 (65.4) | 28.0 (21.6-34.4) | |
Gender | ||||
  Male | 389 (73.0) | 192 (49.4) | 39.7 (29.9-49.5) | 0.019 |
  Female | 144 (27.0) | 86 (59.7) | 28.0 (17.9-38.1) | |
Cancer site | ||||
  Upper third | 156 (29.3) | 80 (51.3) | 32.6 (25.9-39.3) | 0.004 |
  Middle third | 119 (22.3) | 61 (51.3) | 38.9 (9.4-68.4) | |
  Lower third | 222 (41.7) | 112 (50.5) | 42.1 (34.2-49.9) | |
  Whole stomach | 36 (6.8) | 25 (69.4) | 13.2 (10.1-16.3) | |
Pathological type | ||||
  Adeno WD/ID | 131 (24.6) | 59 (45.0) | 42.1 (29.9-54.2) | 0.212 |
  Adeno PD/UN | 299 (56.1) | 160 (53.5) | 34.9 (27.5-42.4) | |
  Signet ring/mucious Ca | 85 (15.9) | 49 (57.6) | 28.0 (10.9-45.1) | |
  Others | 18 (3.4) | 10 (55.6) | 33.7 (20.0-47.5) | |
Surgery type | ||||
  Proximal gastrectomy | 169 (31.7) | 82 (48.5) | 35.9 (20.5-51.3) | < 0.001 |
  Distal gastrectomy | 268 (50.3) | 128 (47.8) | 46.6 (38.1-55.1) | |
  Total gastrectomy | 96 (18.0) | 68 (70.8) | 17.4 (11.3-23.4) | |
Resection type | ||||
  Palliative resection | 11 (2.1) | 11 (100.0) | 9.8 (8.0-11.6) | < 0.001 |
  Curative resection | 522 (97.9) | 267 (51.1) | 38.9 (31.8-46.0) | |
Other organ resection (n) | ||||
  0 | 507 (95.1) | 256(50.5) | 39.3 (32.5-46.0) | < 0.001 |
  1 | 14 (2.6) | 11 (78.6) | 24.1 (9.6-38.7) | |
  2 | 8 (1.5) | 7 (87.5) | 12.4 (2.7-22.2) | |
  ≥ 3 | 4 (0.8) | 4 (100.0) | 13.6 (2.7-24.4) | |
HIPEC | ||||
  No | 505 (94.7) | 251 (49.7) | 39.7 (32.4-47.0) | < 0.001 |
  Yes | 28 (5.3) | 27 (96.4) | 13.4 (9.6-17.2) | |
LN status | ||||
  N0 | 172 (32.3) | 51 (29.7) | 67.3 (59.8-74.8) | < 0.001 |
  N1 | 112 (21.0) | 57 (50.9) | 35.9 (26.8-45.0) | |
  N2 | 143 (26.8) | 86 (60.1) | 27.0 (19.9-34.1) | |
  N3 | 106 (20.0) | 84 (30.5) | 14.4 (12.0-16.8) | |
Tumor invasion | ||||
  T1 | 25 (4.7) | 3 (12.0) | 75.4 (66.4-84.4) | < 0.001 |
  T2 | 85 (15.9) | 19 (22.4) | 72.7 (62.2-83.2) | |
  T3 | 2 (0.4) | 1 (50.0) | 29.1 (10.7-47.4) | |
  T4a | 332 (62.3) | 187 (56.3) | 33.0 (26.6-39.4) | |
  T4b | 89 (16.7) | 68 (76.4) | 14.8 (10.8-18.9) | |
Distant metastases | ||||
  No | 478 (89.7) | 224 (46.9) | 42.5 (34.6-50.4) | < 0.001 |
  Yes | 55 (10.3) | 54 (98.2) | 10.6 (9.0-12.1) | |
TNM staging | ||||
  Stage I | 79 (14.8) | 8 (10.1) | 85.2 (76.1-94.3) | < 0.001 |
  Stage II | 100 (18.8) | 35 (35.0) | 53.9 (46.6-61.3) | |
  Stage IIIA | 80 (15.0) | 38 (47.5) | 40.0 (21.7-58.3) | |
  Stage IIIB | 116 (21.8) | 67 (57.8) | 28.0 (14.9-41.1) | |
  Stage IIIC | 117 (22.0) | 90 (76.9) | 14.8 (10.6-19.1) | |
  Stage IV | 41 (7.7) | 40 (97.6) | 11.1 (9.7-12.4) | |
Postoperative SAE | ||||
  No | 458 (85.9) | 205 (44.8) | 49.8 (32.5-67.0) | < 0.001 |
  Yes | 75 (14.1) | 73 (97.3) | 14.8 (10.0-19.6) | |
Systemic chemotherapy (cycles) | ||||
  0 | 217 (40.7) | 128 (59.0) | 26.3 (19.2-33.4) | 0.001 |
  1 to 6 | 302 (56.7) | 142 (47.0) | 51.7 (36.6-66.9) | |
  > 6 | 14 (2.6) | 8 (57.1) | 37.8 (16.9-58.7) | |
IP chemotherapy | ||||
  No | 521 (97.7) | 267 (51.2) | 37.0 (29.8-44.2) | 0.003 |
  Yes | 12 (2.3) | 11 (91.7) | 11.1 (7.0-15.1) | |